Why the study?
Do temporal patterns of cardiometabolic biomarkers (IGFBP-1, IGFBP-2, IGFBP-7, and adipose FABP-4) predict adverse clinical outcomes in patients with chronic heart failure?
Do temporal patterns of cardiometabolic biomarkers (IGFBP-1, IGFBP-2, IGFBP-7, and adipose FABP-4) predict adverse clinical outcomes in patients with chronic heart failure?
Temporal patterns of specific cardiometabolic biomarkers predict adverse outcomes in chronic heart failure, potentially aiding in prognosis and biomarker-guided therapy.
The temporal patterns of IGFBP-1, IGFBP-2, IGFBP-7, and adipose FABP-4 predict adverse clinical outcomes during outpatient follow-up of patients with CHF and may be clinically relevant as they could help detect more aggressive CHF forms and assess patient prognosis, as well as ultimately aid in designing more effective biomarker-guided therapy.
No takes yet. Share an insight, caveat, or question.
Branković et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: